Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
A phase 1/2 trial of TNG456, Abemaciclib in non-small-cell lung cancer and small-cell lung cancer, run by Tango Therapeutics, Inc., now recruiting.
Overview
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss is a phase 1/2 interventional study registered as NCT06810544 by Tango Therapeutics, Inc., with 191 participants planned, started 2025-03-24 and due to reach its primary completion in 2027-03-31. Interventions recorded: TNG456, abemaciclib. Conditions listed: Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TreatmentTNG260
Shares Tango Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Shares Tango Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Shares Abemaciclib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Shares Abemaciclib, Glioma & glioblastoma.
- TreatmentTNG462
- TargetPRMT5 (MTAP-deleted cancers)
Shares TNG456, Glioma & glioblastoma, Non-small-cell lung cancer.
- PathwayThe cell-cycle engine (cyclins & CDKs)
Shares Abemaciclib, Small-cell lung cancer.